Powder: -20°C for 3 years | In solvent: -80°C for 1 year
GEMSA is a potent inhibitor of enkephalin convertase ( K i =8.8 nM) with analgesic effect[1].
Description | GEMSA is a potent inhibitor of enkephalin convertase ( K i =8.8 nM) with analgesic effect[1]. |
In vitro | GEMSA effectively inhibits the activation of TAFI and porcine CBB, along with preventing the extended lysis time observed in recombinant BAP without causing the lysis of APC fibronectin. Additionally, GEMSA demonstrates inhibition of the increased lysis time associated with porcine CPB, TAFI, and recombinant BAP, APC, exhibiting EC50 values of 0.34 μM, 100 μM, 115 μM, and 90 μM, respectively. |
In vivo | GEMSA administered intracerebroventricularly (ICV) at a dose of 0.1μg/mg every 3 days results in a 75% elevation in both hypothalamic luteinizing hormone-releasing hormone and serum luteinizing hormone levels, alongside a 60% reduction in serum prolactin concentrations in rats [3]. |
Molecular Weight | 235.26 |
Formula | C7H13N3O4S |
CAS No. | 77482-44-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
GEMSA 77482-44-1 Others 2 Guanidinoethylmercaptosuccinic Acid 2Guanidinoethylmercaptosuccinic Acid inhibitor inhibit